Section 80-IE deduction allowed without allocating R&D expenditure to eligible units when conducted in separate standalone facilities

ITAT Mumbai upheld CIT(A)'s decision allowing full deduction under section 80-IE without allocating R&D expenditure to eligible units. The assessee demonstrated that R&D activities were conducted in separate standalone units with independent financials, developing products unrelated to current manufacturing in eligible units. The pharmaceutical R&D process requires 6-10 years before commercial manufacturing, making current R&D expenditure unrelated to present eligible unit operations. The AO's allocation based on sales percentage was rejected as lacking proper nexus between R&D costs and eligible unit products.

---

---

Issues Involved:

1. Allocation of Research and Development (R&D) expenditure to units eligible for deduction under section 80-IE of the Income Tax Act, 1961.

Issue-wise Detailed Analysis:

1. Allocation of R&D Expenditure:

The primary issue in this case is the allocation of R&D expenditure to the units eligible for deduction under section 80-IE of the Income Tax Act, 1961. The Revenue challenged the decision of the learned Commissioner of Income Tax (Appeals) [CIT(A)], who held that the allocation of R&D expenditure by the Assessing Officer (AO) was "baseless and totally unwarranted." The AO had allocated R&D expenses among 80IE units and non-80IE units based on the percentage of sales, arguing that the R&D expenditure was inextricably linked with the business, including products manufactured in units entitled to deductions under Chapter VIA of the Act.

The assessee, engaged in manufacturing pharmaceutical products, argued that its R&D activities were focused on future products and innovations, unrelated to the current manufacturing units. The R&D division was claimed to be working on futuristic research, with no direct relation to the products manufactured in the eligible units during the assessment year under consideration. The assessee provided affidavits and lists of products to substantiate that none of the products developed in the R&D unit were manufactured in the Sikkim unit eligible for section 80-IE deduction during the relevant year.

The CIT(A) sided with the assessee, referencing judicial precedents from the assessee's own cases for previous years (2009-10 and 2010-11), where similar allocations of R&D expenses were deemed unwarranted. The CIT(A) directed the AO to recompute income without allocating R&D expenditure among eligible and non-eligible units.

During the Tribunal hearing, the learned Authorised Representative (AR) for the assessee reiterated that the issue had been resolved in favor of the assessee in previous years. The AR presented an affidavit and product lists to support the claim that R&D activities were unrelated to the Sikkim unit's products. The Departmental Representative countered that the assessee failed to provide substantive evidence during assessment proceedings.

The Tribunal reviewed the submissions and material on record, noting that the R&D units were standalone entities with separate financial statements, focusing on future developments. The Tribunal found that the products developed in the R&D units were unrelated to those manufactured in the eligible units. It was highlighted that pharmaceutical R&D involves lengthy processes and approvals, distinguishing it from other industries. The Tribunal found no merit in the AO's findings that R&D products were manufactured in eligible units during the relevant year. The assumption that R&D expenditure should be allocated for computing deductions under section 80-IE was deemed unfounded.

The Tribunal upheld the CIT(A)'s decision, referencing consistent findings in the assessee's favor from previous Tribunal orders for assessment years 2011-12 and 2012-13. The Tribunal concluded that the allocation of R&D expenses was unjustified, and the Revenue's appeal for both assessment years 2018-19 and 2021-22 was dismissed. The decision for the assessment year 2018-19 was applied mutatis mutandis to the appeal for 2021-22, leading to the dismissal of the Revenue's appeal for both years.

The judgment was pronounced in open court on 10/10/2024, affirming the CIT(A)'s order and dismissing the Revenue's appeals.

---